Announcements Trials
Browse Landscape

Status

No longer available 2Approved for marketing 2Available 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 65Observational 28Expanded_access 5

Sponsor

Cancer Type

Endocrine 5CNS 5Head & Neck 1

Conditions

Pheochromocytoma 7Neuroendocrine Tumors 7Paraganglioma 5Neuroblastoma 5Insulinoma 3Carcinoid Tumor 3Recurrence 2Neoplasms 2Hypoglycemia 2Hyperinsulinism 2Carcinoma, Medullary 2Adenoma, Islet Cell 2Thyroid cancer, medullary 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Liposarcoma 1Fibrosarcoma 1Congenital Hyperinsulinism 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Beckwith-Wiedemann Syndrome 1

Interventions

3-Iodobenzylguanidine 4fluorodopa F 18 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Expanded_access × Paraganglioma × Endocrine × Clear all
NCT01838187 2023-08-18

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Children's Hospital Medical Center, Cincinnati

No longer available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT01590680 2023-02-28

Expanded Access Protocol Using 131I-MIBG

Jubilant DraxImage Inc.

Available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT02431715 2023-02-21

18F-FDOPA PET in Neuroendocrine Tumours

British Columbia Cancer Agency

No longer available
CNSEndocrineHead & Neck

Thyroid cancer, medullary, Carcinoid Tumor, Insulinoma, Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT01377532 2020-05-06

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

University of California, San Francisco

Approved for marketing
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

NCT02961491 2019-01-30

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Approved for marketing
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡